ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Sihuan Given SFDA Approval to Start Clinical Trial of Innovative Antibiotic
publication date: Jan 22, 2013
Sihuan Pharma received approval from the SFDA to begin clinical trials of the company’s new antibiotic, benapenem, a Category 1.1 drug that is a member of the carbapenem class of antibiotics. Both the APIs and injection form of the drug are patented. Sihuan said the antibiotic will begin its clinical trial in the first half of 2013, the company’s third Category 1 innovative drug to enter human trials. More details....
Stock Symbol: (HK: 0460)
Share this with colleagues:
This article is available for purchase - please click here for details.
Sorry this page is available to subscribers only. If you're not a subscriber why not subscribe today?